Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting

Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day ...

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment ...

PPD looking for 3 girls missing from treatment center

Portsmouth police are searching for two missing teens and one missing adolescent last seen early Sunday morning at the Harbor ...
Business Wire

PPD Named Clinical Research Company of the Year for Second Consecutive Year

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) was named “Clinical Research Company of the Year” at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London ...
MedCity News

PPD’s sale to private equity: How the CRO M&A deal got done

Days before PPD‘s (NYSE:PPDI) $3.9 billion sale to private equity was announced on October 3, the clinical research organization’s lead independent director, Ernest Mario, was busy trading e-mails and ...

Lipocine Inc.: Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative ...